{"entity":{"type":"insider","cik":"0001366074","url":"/insider/0001366074","json_url":"/insider/0001366074.json","name":"Lappe Mark","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":98,"n_filings":39,"first":"2007-11-02","last":"2024-09-16","span_basis":"filed_date"},"name_variants":[{"name":"Lappe Mark","source":"filing","n_filings":39,"first_seen":"2007-11-02","last_seen":"2024-09-16"}],"transactions":[{"id":2073080,"accession":"0002007919-24-000049","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0002007919-24-000049","line_url":"/filing/0002007919-24-000049#line-2","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13037.0,"shares_display":"13,037","price_per_share":17.13,"price_display":"17.13","price_state":"stated","total_value":223323.81,"total_display":"223,323.81","total_whole":"223,324","shares_owned_after":705548.0,"shares_owned_after_display":"705,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-16","scope":"insider"},{"id":2073078,"accession":"0002007919-24-000049","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0002007919-24-000049","line_url":"/filing/0002007919-24-000049#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":26963.0,"shares_display":"26,963","price_per_share":15.05,"price_display":"15.05","price_state":"stated","total_value":405793.15,"total_display":"405,793.15","total_whole":"405,793","shares_owned_after":692511.0,"shares_owned_after_display":"692,511","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-12","filed_date":"2024-09-16","scope":"insider"},{"id":3234552,"accession":"0002007919-24-000045","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0002007919-24-000045","line_url":"/filing/0002007919-24-000045#line-3","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8500.0,"shares_display":"8,500","price_per_share":15.19,"price_display":"15.19","price_state":"stated","total_value":129115.0,"total_display":"129,115.00","total_whole":"129,115","shares_owned_after":665548.0,"shares_owned_after_display":"665,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-10","scope":"insider"},{"id":3234547,"accession":"0002007919-24-000045","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0002007919-24-000045","line_url":"/filing/0002007919-24-000045#line-2","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9500.0,"shares_display":"9,500","price_per_share":15.21,"price_display":"15.21","price_state":"stated","total_value":144495.0,"total_display":"144,495.00","total_whole":"144,495","shares_owned_after":657048.0,"shares_owned_after_display":"657,048","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-10","scope":"insider"},{"id":3234541,"accession":"0002007919-24-000045","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0002007919-24-000045","line_url":"/filing/0002007919-24-000045#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":26000.0,"shares_display":"26,000","price_per_share":15.29,"price_display":"15.29","price_state":"stated","total_value":397540.0,"total_display":"397,540.00","total_whole":"397,540","shares_owned_after":647548.0,"shares_owned_after_display":"647,548","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-06","filed_date":"2024-09-10","scope":"insider"},{"id":2294746,"accession":"0001739614-24-000037","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001739614-24-000037","line_url":"/filing/0001739614-24-000037","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":15.81314,"price_display":"15.81","price_state":"stated","total_value":316262.8,"total_display":"316,262.80","total_whole":"316,263","shares_owned_after":160288.0,"shares_owned_after_display":"160,288","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-09-03","filed_date":"2024-09-03","scope":"insider","n_lines":2},{"id":2294736,"accession":"0001739614-24-000037","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-24-000037","line_url":"/filing/0001739614-24-000037#line-2","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":14.02,"price_display":"14.02","price_state":"stated","total_value":140200.0,"total_display":"140,200.00","total_whole":"140,200","shares_owned_after":145000.0,"shares_owned_after_display":"145,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-30","filed_date":"2024-09-03","scope":"insider"},{"id":2294730,"accession":"0001739614-24-000037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-24-000037","line_url":"/filing/0001739614-24-000037#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":14.03,"price_display":"14.03","price_state":"stated","total_value":140300.0,"total_display":"140,300.00","total_whole":"140,300","shares_owned_after":135000.0,"shares_owned_after_display":"135,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-29","filed_date":"2024-09-03","scope":"insider"},{"id":2833737,"accession":"0002007919-24-000038","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0002007919-24-000038","line_url":"/filing/0002007919-24-000038#line-2","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12945.0,"shares_display":"12,945","price_per_share":12.93,"price_display":"12.93","price_state":"stated","total_value":167378.85,"total_display":"167,378.85","total_whole":"167,379","shares_owned_after":54865.0,"shares_owned_after_display":"54,865","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-21","filed_date":"2024-08-22","scope":"insider"},{"id":2833734,"accession":"0002007919-24-000038","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0002007919-24-000038","line_url":"/filing/0002007919-24-000038#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx Biosciences, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27055.0,"shares_display":"27,055","price_per_share":12.97,"price_display":"12.97","price_state":"stated","total_value":350903.35,"total_display":"350,903.35","total_whole":"350,903","shares_owned_after":41920.0,"shares_owned_after_display":"41,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-20","filed_date":"2024-08-22","scope":"insider"},{"id":8717291,"accession":"0001739614-23-000014","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-23-000014","line_url":"/filing/0001739614-23-000014#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Mark; Lappe Family Trust","owner_display_name":"Lappe Mark","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":60.0,"shares_display":"60","price_per_share":25.0208,"price_display":"25.02","price_state":"stated","total_value":1501.248,"total_display":"1,501.25","total_whole":"1,501","shares_owned_after":2486192.0,"shares_owned_after_display":"2,486,192","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-28","filed_date":"2023-03-01","scope":"insider"},{"id":8617962,"accession":"0001739614-23-000010","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001739614-23-000010","line_url":"/filing/0001739614-23-000010","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Mark; Lappe Family Trust","owner_display_name":"Lappe Mark","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4335.0,"shares_display":"4,335","price_per_share":25.715852387543254,"price_display":"25.72","price_state":"stated","total_value":111478.2201,"total_display":"111,478.22","total_whole":"111,478","shares_owned_after":2486315.0,"shares_owned_after_display":"2,486,315","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-24","filed_date":"2023-01-24","scope":"insider","n_lines":2},{"id":8617958,"accession":"0001739614-23-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-23-000010","line_url":"/filing/0001739614-23-000010#line-1","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Mark; Lappe Family Trust","owner_display_name":"Lappe Mark","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21665.0,"shares_display":"21,665","price_per_share":25.3572,"price_display":"25.36","price_state":"stated","total_value":549363.738,"total_display":"549,363.74","total_whole":"549,364","shares_owned_after":2490587.0,"shares_owned_after_display":"2,490,587","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-23","filed_date":"2023-01-24","scope":"insider"},{"id":6363515,"accession":"0001739614-22-000130","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-22-000130","line_url":"/filing/0001739614-22-000130","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Family Trust; Lappe Mark","owner_display_name":"Lappe Family Trust","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26000.0,"shares_display":"26,000","price_per_share":25.5555138,"price_display":"25.56","price_state":"stated","total_value":664443.3588,"total_display":"664,443.36","total_whole":"664,443","shares_owned_after":2513006.0,"shares_owned_after_display":"2,513,006","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-19","filed_date":"2022-12-20","scope":"insider","n_lines":2},{"id":6836456,"accession":"0001739614-22-000124","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001739614-22-000124","line_url":"/filing/0001739614-22-000124","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Family Trust; Lappe Mark","owner_display_name":"Lappe Family Trust","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26000.0,"shares_display":"26,000","price_per_share":27.88114535,"price_display":"27.88","price_state":"stated","total_value":724909.7791,"total_display":"724,909.78","total_whole":"724,910","shares_owned_after":2557293.0,"shares_owned_after_display":"2,557,293","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-17","filed_date":"2022-11-18","scope":"insider","n_lines":7},{"id":6402809,"accession":"0001739614-22-000107","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001739614-22-000107","line_url":"/filing/0001739614-22-000107","is_derivative":false,"issuer_cik":"0001366074","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001366074","owner_cik":null,"owner_name":"Lappe Family Trust; Lappe Mark","owner_display_name":"Lappe Family Trust","owner_url":null,"role":"Director, Officer (Chief Executive Officer), Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":26000.0,"shares_display":"26,000","price_per_share":29.593970103846154,"price_display":"29.59","price_state":"stated","total_value":769443.2227,"total_display":"769,443.22","total_whole":"769,443","shares_owned_after":2567265.0,"shares_owned_after_display":"2,567,265","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-17","filed_date":"2022-10-18","scope":"insider","n_lines":4},{"id":8966258,"accession":"0001140361-11-017510","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-11-017510","line_url":"/filing/0001140361-11-017510#line-2","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3799380.0,"shares_display":"3,799,380","price_per_share":0.61,"price_display":"0.61","price_state":"stated","total_value":2317621.8,"total_display":"2,317,621.80","total_whole":"2,317,622","shares_owned_after":4349432.0,"shares_owned_after_display":"4,349,432","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-03-16","filed_date":"2011-03-17","scope":"insider"},{"id":8966257,"accession":"0001140361-11-017510","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-11-017510","line_url":"/filing/0001140361-11-017510#line-1","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":193234.0,"shares_display":"193,234","price_per_share":0.76,"price_display":"0.76","price_state":"stated","total_value":146857.84,"total_display":"146,857.84","total_whole":"146,858","shares_owned_after":8148812.0,"shares_owned_after_display":"8,148,812","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-03-15","filed_date":"2011-03-17","scope":"insider"},{"id":9072713,"accession":"0001140361-11-010589","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-11-010589","line_url":"/filing/0001140361-11-010589#line-2","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":57600.0,"shares_display":"57,600","price_per_share":0.97,"price_display":"0.97","price_state":"stated","total_value":55872.0,"total_display":"55,872.00","total_whole":"55,872","shares_owned_after":8342046.0,"shares_owned_after_display":"8,342,046","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-16","filed_date":"2011-02-17","scope":"insider"},{"id":9072712,"accession":"0001140361-11-010589","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-11-010589","line_url":"/filing/0001140361-11-010589#line-1","is_derivative":false,"issuer_cik":"0001261734","issuer_name":"AEOLUS PHARMACEUTICALS, INC.","issuer_ticker":"AOLS","issuer_name_source":null,"issuer_url":"/issuer/0001261734","owner_cik":null,"owner_name":"Efficacy Biotech Fund LTD; Efficacy Capital, Ltd.; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Fund LTD","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":0.95,"price_display":"0.95","price_state":"stated","total_value":6650.0,"total_display":"6,650.00","total_whole":"6,650","shares_owned_after":8399646.0,"shares_owned_after_display":"8,399,646","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-02-15","filed_date":"2011-02-17","scope":"insider"},{"id":5669718,"accession":"0001140361-09-029903","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":76703.0,"shares_display":"76,703","price_per_share":0.6545,"price_display":"0.65","price_state":"stated","total_value":50202.1135,"total_display":"50,202.11","total_whole":"50,202","shares_owned_after":2552233.0,"shares_owned_after_display":"2,552,233","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-21","filed_date":"2009-12-21","scope":"insider"},{"id":5669717,"accession":"0001140361-09-029903","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30000.0,"shares_display":"30,000","price_per_share":0.676,"price_display":"0.68","price_state":"stated","total_value":20280.0,"total_display":"20,280.00","total_whole":"20,280","shares_owned_after":2628936.0,"shares_owned_after_display":"2,628,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-18","filed_date":"2009-12-21","scope":"insider"},{"id":5669716,"accession":"0001140361-09-029903","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-029903","line_url":"/filing/0001140361-09-029903#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50100.0,"shares_display":"50,100","price_per_share":0.703,"price_display":"0.70","price_state":"stated","total_value":35220.3,"total_display":"35,220.30","total_whole":"35,220","shares_owned_after":2658936.0,"shares_owned_after_display":"2,658,936","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-17","filed_date":"2009-12-21","scope":"insider"},{"id":5758296,"accession":"0001140361-09-029245","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":181700.0,"shares_display":"181,700","price_per_share":0.67,"price_display":"0.67","price_state":"stated","total_value":121739.0,"total_display":"121,739.00","total_whole":"121,739","shares_owned_after":2709036.0,"shares_owned_after_display":"2,709,036","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-15","filed_date":"2009-12-15","scope":"insider"},{"id":5758293,"accession":"0001140361-09-029245","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":77900.0,"shares_display":"77,900","price_per_share":0.699,"price_display":"0.70","price_state":"stated","total_value":54452.1,"total_display":"54,452.10","total_whole":"54,452","shares_owned_after":2890736.0,"shares_owned_after_display":"2,890,736","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-14","filed_date":"2009-12-15","scope":"insider"},{"id":5758288,"accession":"0001140361-09-029245","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-029245","line_url":"/filing/0001140361-09-029245#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD; Lappe Mark","owner_display_name":"Efficacy Biotech Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":126500.0,"shares_display":"126,500","price_per_share":0.696,"price_display":"0.70","price_state":"stated","total_value":88044.0,"total_display":"88,044.00","total_whole":"88,044","shares_owned_after":2968636.0,"shares_owned_after_display":"2,968,636","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-11","filed_date":"2009-12-15","scope":"insider"},{"id":5588364,"accession":"0001140361-09-027917","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":262000.0,"shares_display":"262,000","price_per_share":0.6957,"price_display":"0.70","price_state":"stated","total_value":182273.4,"total_display":"182,273.40","total_whole":"182,273","shares_owned_after":3095136.0,"shares_owned_after_display":"3,095,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-02","filed_date":"2009-12-02","scope":"insider"},{"id":5588363,"accession":"0001140361-09-027917","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":131000.0,"shares_display":"131,000","price_per_share":0.7084,"price_display":"0.71","price_state":"stated","total_value":92800.4,"total_display":"92,800.40","total_whole":"92,800","shares_owned_after":3357136.0,"shares_owned_after_display":"3,357,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-12-01","filed_date":"2009-12-02","scope":"insider"},{"id":5588362,"accession":"0001140361-09-027917","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-027917","line_url":"/filing/0001140361-09-027917#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Master Fund Ltd.; Efficacy Biotech Fund LTD; Efficacy Biotech Fund L.P.; Lappe Mark","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":148000.0,"shares_display":"148,000","price_per_share":0.7127,"price_display":"0.71","price_state":"stated","total_value":105479.6,"total_display":"105,479.60","total_whole":"105,480","shares_owned_after":3488136.0,"shares_owned_after_display":"3,488,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-30","filed_date":"2009-12-02","scope":"insider"},{"id":5843395,"accession":"0001140361-09-027215","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-3","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":227000.0,"shares_display":"227,000","price_per_share":0.7013,"price_display":"0.70","price_state":"stated","total_value":159195.1,"total_display":"159,195.10","total_whole":"159,195","shares_owned_after":3636136.0,"shares_owned_after_display":"3,636,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-23","filed_date":"2009-11-23","scope":"insider"},{"id":5843393,"accession":"0001140361-09-027215","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":215000.0,"shares_display":"215,000","price_per_share":0.7069,"price_display":"0.71","price_state":"stated","total_value":151983.5,"total_display":"151,983.50","total_whole":"151,984","shares_owned_after":3863136.0,"shares_owned_after_display":"3,863,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-20","filed_date":"2009-11-23","scope":"insider"},{"id":5843390,"accession":"0001140361-09-027215","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-09-027215","line_url":"/filing/0001140361-09-027215#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Lappe Mark; Efficacy Biotech Fund L.P.; Efficacy Biotech Master Fund Ltd.; Efficacy Capital, Ltd.; Efficacy Biotech Fund LTD","owner_display_name":"Lappe Mark","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":214000.0,"shares_display":"214,000","price_per_share":0.7487,"price_display":"0.75","price_state":"stated","total_value":160221.8,"total_display":"160,221.80","total_whole":"160,222","shares_owned_after":4078136.0,"shares_owned_after_display":"4,078,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2009-11-19","filed_date":"2009-11-23","scope":"insider"},{"id":3763307,"accession":"0001181431-08-059701","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-08-059701","line_url":"/filing/0001181431-08-059701#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11300.0,"shares_display":"11,300","price_per_share":7.76,"price_display":"7.76","price_state":"stated","total_value":87688.0,"total_display":"87,688.00","total_whole":"87,688","shares_owned_after":4292136.0,"shares_owned_after_display":"4,292,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-31","filed_date":"2008-11-04","scope":"insider"},{"id":3678184,"accession":"0001104659-08-067952","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-067952","line_url":"/filing/0001104659-08-067952#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Biotech Master Fund Ltd.; Lappe Mark; Efficacy Biotech Fund LTD; Kayyem Jon Faiz; Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.","owner_display_name":"Efficacy Biotech Master Fund Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11300.0,"shares_display":"11,300","price_per_share":7.76,"price_display":"7.76","price_state":"stated","total_value":87688.0,"total_display":"87,688.00","total_whole":"87,688","shares_owned_after":4292136.0,"shares_owned_after_display":"4,292,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-31","filed_date":"2008-11-04","scope":"insider"},{"id":3849382,"accession":"0001181431-08-059021","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-08-059021","line_url":"/filing/0001181431-08-059021#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24400.0,"shares_display":"24,400","price_per_share":6.97,"price_display":"6.97","price_state":"stated","total_value":170068.0,"total_display":"170,068.00","total_whole":"170,068","shares_owned_after":4280836.0,"shares_owned_after_display":"4,280,836","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-29","filed_date":"2008-10-30","scope":"insider"},{"id":3706766,"accession":"0001104659-08-067039","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-08-067039","line_url":"/filing/0001104659-08-067039#line-2","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":24400.0,"shares_display":"24,400","price_per_share":6.97,"price_display":"6.97","price_state":"stated","total_value":170068.0,"total_display":"170,068.00","total_whole":"170,068","shares_owned_after":4280836.0,"shares_owned_after_display":"4,280,836","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-29","filed_date":"2008-10-30","scope":"insider"},{"id":3849379,"accession":"0001181431-08-059021","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001181431-08-059021","line_url":"/filing/0001181431-08-059021#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":"0001366074","owner_name":"Lappe Mark","owner_display_name":"Lappe Mark","owner_url":"/insider/0001366074","role":"Director, Ten percent owner","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9892.0,"shares_display":"9,892","price_per_share":6.87,"price_display":"6.87","price_state":"stated","total_value":67958.04,"total_display":"67,958.04","total_whole":"67,958","shares_owned_after":4256436.0,"shares_owned_after_display":"4,256,436","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-28","filed_date":"2008-10-30","scope":"insider"},{"id":3706765,"accession":"0001104659-08-067039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-08-067039","line_url":"/filing/0001104659-08-067039#line-1","is_derivative":false,"issuer_cik":"0000897075","issuer_name":"REPROS THERAPEUTICS INC.","issuer_ticker":"RPRX","issuer_name_source":null,"issuer_url":"/issuer/0000897075","owner_cik":null,"owner_name":"Efficacy Capital, Ltd.; Efficacy Biotech Fund L.P.; Efficacy Biotech Fund LTD; Lappe Mark; Efficacy Biotech Master Fund Ltd.; Kayyem Jon Faiz","owner_display_name":"Efficacy Capital, Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9892.0,"shares_display":"9,892","price_per_share":6.87,"price_display":"6.87","price_state":"stated","total_value":67958.04,"total_display":"67,958.04","total_whole":"67,958","shares_owned_after":4256436.0,"shares_owned_after_display":"4,256,436","ownership_form":"I","is_10b5_1":null,"transaction_date":"2008-10-28","filed_date":"2008-10-30","scope":"insider"}],"collapsed":true,"next_cursor":"2008-10-28|3706765","ledger_fault":false,"count":{"value":21,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":21,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":21},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002007919","name":"Inhibrx Biosciences, Inc.","url":"/issuer/0002007919","role":"Director, Officer (Chief Executive Officer)","n_filings":4,"first_seen":"2024-08-22","last_seen":"2024-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001739614","name":"Inhibrx, Inc.","url":"/issuer/0001739614","role":"Director, Officer (Chief Executive Officer)","n_filings":5,"first_seen":"2022-10-18","last_seen":"2023-03-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001261734","name":"AEOLUS PHARMACEUTICALS, INC.","url":"/issuer/0001261734","role":"Ten percent owner","n_filings":2,"first_seen":"2011-02-17","last_seen":"2011-03-17"},{"type":"issuer","type_label":"ISSUER","cik":"0000897075","name":"REPROS THERAPEUTICS INC.","url":"/issuer/0000897075","role":"Director, Ten percent owner","n_filings":28,"first_seen":"2007-11-02","last_seen":"2009-12-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001366074","retrieved_at":"2026-08-27T17:12:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}